David Olmos Hidalgo
Impact in
- Pulmonary and Respiratory Medicine top 0.1%
- Prostate Cancer Treatment and Research
- Prostate Cancer Diagnosis and Treatment
- Cancer Research top 0.5%
- Cancer Genomics and Diagnostics
- Cancer, Lipids, and Metabolism
Papers in
-
- Prostate Cancer Treatment and Research 106
- Sarcoma Diagnosis and Treatment 15
- Prostate Cancer Diagnosis and Treatment 14
- Oncology 49
- PARP inhibition in cancer therapy 22
- Co-authors
- Johann Sebastian De Bono (57 shared papers)Fred Saad (18 shared papers)Shahneen Kaur Sandhu (26 shared papers)Joaquı́n Mateo (12 shared papers)Gerhardt Attard (20 shared papers)Ian Robert Judson (16 shared papers)Stan B. Kaye (19 shared papers)Kim N. Chi (10 shared papers)
- Journals
- Annals of Oncology (45 papers)Journal of Clinical Oncology (15 papers)European Urology (14 papers)British Journal of Cancer (13 papers)Clinical Cancer Research (11 papers)
- Partner nations
- SpainUnited KingdomUnited States
In The Last Decade
David Olmos Hidalgo
196 papers receiving 15.0k citations
David Olmos Hidalgo's Hit Papers
Peers
Comparison fields: 5 of 147
- Pulmonary and Respiratory Medicine 8.4k
- Cancer Research 3.3k
- Oncology 4.6k
- Endocrinology, Diabetes and Metabolism 871
- Molecular Biology 3.8k
Countries citing papers authored by David Olmos Hidalgo
This map shows the geographic impact of David Olmos Hidalgo's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David Olmos Hidalgo with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David Olmos Hidalgo more than expected).
Fields of papers citing papers by David Olmos Hidalgo
This network shows the impact of papers produced by David Olmos Hidalgo. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David Olmos Hidalgo. The network helps show where David Olmos Hidalgo may publish in the future.
Co-authors
The 25 scholars most cited alongside David Olmos Hidalgo, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 201 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Olaparib for Metastatic Castration-Resistant Prostate Cancer Hit paper breakdown → | 2020 | 1753 |
| 2 | Apalutamide Treatment and Metastasis-free Survival in Prostate Cancer Hit paper breakdown → | 2018 | 1025 |
| 3 | Germline BRCA Mutations Are Associated With Higher Risk of Nodal Involvement, Distant Metastasis, and Poor Survival Outcomes in Prostate Cancer Hit paper breakdown → | 2013 | 665 |
| 4 | Survival with Olaparib in Metastatic Castration-Resistant Prostate Cancer Hit paper breakdown → | 2020 | 603 |
| 5 | Selective Inhibition of CYP17 With Abiraterone Acetate Is Highly Active in the Treatment of Castration-Resistant Prostate Cancer Hit paper breakdown → | 2009 | 499 |
| 6 | 2011 | 491 | |
| 7 | 2009 | 474 | |
| 8 | Circulating Tumor Cell Biomarker Panel As an Individual-Level Surrogate for Survival in Metastatic Castration-Resistant Prostate Cancer Hit paper breakdown → | 2015 | 334 |
| 9 | 2010 | 329 | |
| 10 | PROREPAIR-B: A Prospective Cohort Study of the Impact of Germline DNA Repair Mutations on the Outcomes of Patients With Metastatic Castration-Resistant Prostate Cancer Hit paper breakdown → | 2019 | 313 |
| 11 | 2014 | 299 | |
| 12 | 2009 | 291 | |
| 13 | Ipatasertib plus abiraterone and prednisolone in metastatic castration-resistant prostate cancer (IPATential150): a multicentre, randomised, double-blind, phase 3 trial Hit paper breakdown → | 2021 | 265 |
| 14 | 2015 | 264 | |
| 15 | 2013 | 244 | |
| 16 | Niraparib and Abiraterone Acetate for Metastatic Castration-Resistant Prostate Cancer Hit paper breakdown → | 2023 | 240 |
| 17 | 2020 | 214 | |
| 18 | 2008 | 213 | |
| 19 | 2012 | 211 | |
| 20 | 2016 | 193 |
About David Olmos Hidalgo
David Olmos Hidalgo is a scholar working on Pulmonary and Respiratory Medicine, Oncology, Cancer Research, Radiology, Nuclear Medicine and Imaging and Statistics and Probability, having authored 201 papers that have together received 15.3k indexed citations. Recurring topics across this work include Prostate Cancer Treatment and Research (106 papers), PARP inhibition in cancer therapy (22 papers), Radiopharmaceutical Chemistry and Applications (18 papers), Sarcoma Diagnosis and Treatment (15 papers), Prostate Cancer Diagnosis and Treatment (14 papers), Cancer, Lipids, and Metabolism (13 papers), Statistical Methods in Clinical Trials (10 papers) and Cancer Genomics and Diagnostics (8 papers). The work is most often cited by research in Pulmonary and Respiratory Medicine (8.4k citations), Cancer Research (3.3k citations), Oncology (4.6k citations), Endocrinology, Diabetes and Metabolism (871 citations) and Molecular Biology (3.8k citations). David Olmos Hidalgo has collaborated with scholars based in Spain, United Kingdom and United States. Frequent co-authors include Johann Sebastian De Bono, Fred Saad, Shahneen Kaur Sandhu, Joaquı́n Mateo, Gerhardt Attard, Ian Robert Judson, Stan B. Kaye, Kim N. Chi, Neeraj Agarwal and Carrie A. Adelman. Their work appears in journals such as Annals of Oncology, Journal of Clinical Oncology, European Urology, British Journal of Cancer and Clinical Cancer Research.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.